IN2014MN02104A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02104A IN2014MN02104A IN2104MUN2014A IN2014MN02104A IN 2014MN02104 A IN2014MN02104 A IN 2014MN02104A IN 2104MUN2014 A IN2104MUN2014 A IN 2104MUN2014A IN 2014MN02104 A IN2014MN02104 A IN 2014MN02104A
- Authority
- IN
- India
- Prior art keywords
- hydroxyacrylamide
- dihydro
- oxo
- ethyl
- compound
- Prior art date
Links
- HQVFKSDWNYVAQD-UHFFFAOYSA-N n-hydroxyprop-2-enamide Chemical compound ONC(=O)C=C HQVFKSDWNYVAQD-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- MOGMVSJVDRLGJN-UHFFFAOYSA-N 2-(2-phenylethyl)quinazoline Chemical compound N=1C=C2C=CC=CC2=NC=1CCC1=CC=CC=C1 MOGMVSJVDRLGJN-UHFFFAOYSA-N 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 102000003964 Histone deacetylase Human genes 0.000 abstract 1
- 108090000353 Histone deacetylase Proteins 0.000 abstract 1
- -1 chloro 2 ethyl Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261622127P | 2012-04-10 | 2012-04-10 | |
| PCT/US2013/035004 WO2013154870A1 (en) | 2012-04-10 | 2013-04-02 | Histone deacetylases (hdacs) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02104A true IN2014MN02104A (enrdf_load_stackoverflow) | 2015-09-04 |
Family
ID=49292802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2104MUN2014 IN2014MN02104A (enrdf_load_stackoverflow) | 2012-04-10 | 2013-04-02 |
Country Status (13)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10052739B2 (en) | 2011-09-12 | 2018-08-21 | Applied Materials, Inc. | Carrier head with composite plastic portions |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| KR102365651B1 (ko) | 2013-10-04 | 2022-02-21 | 인피니티 파마슈티칼스, 인코포레이티드 | 헤테로사이클릭 화합물 및 그의 용도 |
| EP3114109A4 (en) * | 2014-03-07 | 2017-10-18 | The Johns Hopkins University | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) |
| CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| US10807944B2 (en) | 2014-04-04 | 2020-10-20 | University Of Florida Research Foundation, Inc. | HDAC inhibitor compounds and methods of treatment |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| EP3350183B1 (en) | 2015-09-14 | 2025-04-02 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| BR112019024111A2 (pt) | 2017-05-16 | 2020-06-02 | Annji Pharmaceutical Co., Ltd | Inibidores de histona desacetilases (hdacs) |
| GB201820450D0 (en) | 2018-12-14 | 2019-01-30 | Z Factor Ltd | Compound and its use for the treatment of alpha1-antitryspin deficiency |
| GB201918404D0 (en) * | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of aplha1-antitrypsin deficiency |
| KR20210116830A (ko) * | 2020-03-17 | 2021-09-28 | 충북대학교 산학협력단 | 신규한 4-옥소퀴나졸린-기반 n-하이드록시프로펜아미드 및 이의 용도 |
| CN111517977B (zh) * | 2020-05-28 | 2023-05-23 | 爱斯特（成都）生物制药股份有限公司 | 一种合成2,4-二氟-3-三甲基乙酰胺基苯甲酸的方法 |
| CN115843292A (zh) * | 2020-06-08 | 2023-03-24 | 安基生技新药股份有限公司 | 用作选择性hdac6抑制剂的喹唑啉衍生物 |
| WO2023159155A1 (en) * | 2022-02-18 | 2023-08-24 | Pivalent Therapeutics, Inc. | Inhibitors of phosphoinositide 3-kinase (pi3k) and uses thereof |
| WO2025029683A1 (en) * | 2023-07-28 | 2025-02-06 | Cogent Biosciences, Inc. | Pi3k inhibitors |
| AU2024364867A1 (en) * | 2023-10-18 | 2025-07-24 | Gilva Therapeutics Co., Ltd. | Quinazolinone derivatives for hdac inhibition |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH464935A (de) * | 1965-05-12 | 1968-11-15 | Sumitomo Chemical Co | Verfahren zur Herstellung neuer Chinazolinonderivate |
| FR6001M (enrdf_load_stackoverflow) * | 1966-12-02 | 1968-04-29 | ||
| ZA705270B (en) * | 1969-08-02 | 1971-04-28 | Sumitomo Chemical Co | Novel quinazolinone derivatives and a process for production thereof |
| US4054658A (en) * | 1974-02-06 | 1977-10-18 | William H. Rorer, Inc. | Therapeutic compositions containing methaqualone |
| NZ192392A (en) | 1978-12-19 | 1983-02-15 | M Ishikawa | 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones |
| JP3488890B2 (ja) * | 1993-11-09 | 2004-01-19 | アグロカネショウ株式会社 | ３−ｎ−置換キナゾリノン誘導体、その製造法および該化合物を含有する除草剤 |
| EP1524262A1 (en) * | 2000-03-24 | 2005-04-20 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| EP1280764B1 (en) * | 2000-03-24 | 2010-11-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| MXPA05004328A (es) * | 2002-11-04 | 2005-08-02 | Nps Pharma Inc | Compuestos de quinazolinona como calciliticos. |
| ITMI20041869A1 (it) | 2004-10-01 | 2005-01-01 | Dac Srl | Nuovi inibitori delle istone deacetilasi |
| WO2007011623A1 (en) * | 2005-07-15 | 2007-01-25 | Schering Corporation | Quinazoline derivatives useful in cancer treatment |
| NZ566073A (en) | 2005-09-21 | 2011-08-26 | 4Sc Ag | Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors |
| GB0525068D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0624187D0 (en) | 2006-12-04 | 2007-01-10 | Jackson William P | HDAC inhibitors |
| WO2008087514A2 (en) | 2007-01-17 | 2008-07-24 | Orchid Research Laboratories Limited | Hdac inhibitors |
| WO2009026446A2 (en) | 2007-08-21 | 2009-02-26 | Arqule, Inc. | Hdac inhibitors |
| EP2200439B1 (en) | 2007-10-01 | 2017-03-22 | Lixte Biotechnology, Inc. | Hdac inhibitors |
| JP5838157B2 (ja) | 2009-07-22 | 2015-12-24 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ | Ｈｄａｃ阻害剤およびそれを用いる治療法 |
-
2013
- 2013-04-02 KR KR1020147031519A patent/KR101781922B1/ko active Active
- 2013-04-02 IN IN2104MUN2014 patent/IN2014MN02104A/en unknown
- 2013-04-02 EP EP13775887.6A patent/EP2836484B1/en active Active
- 2013-04-02 WO PCT/US2013/035004 patent/WO2013154870A1/en active Application Filing
- 2013-04-02 AU AU2013246278A patent/AU2013246278B2/en active Active
- 2013-04-02 BR BR112014025122-3A patent/BR112014025122B1/pt active IP Right Grant
- 2013-04-02 CN CN201380030630.7A patent/CN104364237B/zh active Active
- 2013-04-02 US US13/855,525 patent/US9387209B2/en active Active
- 2013-04-02 JP JP2015505789A patent/JP6258918B2/ja active Active
- 2013-04-02 ES ES13775887.6T patent/ES2630062T3/es active Active
- 2013-04-02 RU RU2014144142A patent/RU2629947C2/ru active
- 2013-04-10 TW TW102112723A patent/TWI481597B/zh active
-
2014
- 2014-10-07 IL IL235053A patent/IL235053A/en active IP Right Grant
-
2015
- 2015-03-23 US US14/666,169 patent/US9155739B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2836484B1 (en) | 2017-06-14 |
| US9387209B2 (en) | 2016-07-12 |
| EP2836484A1 (en) | 2015-02-18 |
| TW201345898A (zh) | 2013-11-16 |
| CN104364237A (zh) | 2015-02-18 |
| JP2015512939A (ja) | 2015-04-30 |
| IL235053A (en) | 2017-09-28 |
| RU2014144142A (ru) | 2016-06-10 |
| US20130267542A1 (en) | 2013-10-10 |
| BR112014025122B1 (pt) | 2022-08-16 |
| KR101781922B1 (ko) | 2017-09-26 |
| EP2836484A4 (en) | 2015-09-02 |
| AU2013246278A1 (en) | 2014-11-13 |
| KR20150000901A (ko) | 2015-01-05 |
| ES2630062T3 (es) | 2017-08-17 |
| US20150196563A1 (en) | 2015-07-16 |
| BR112014025122A2 (pt) | 2021-07-06 |
| JP6258918B2 (ja) | 2018-01-10 |
| AU2013246278B2 (en) | 2016-11-03 |
| WO2013154870A1 (en) | 2013-10-17 |
| CN104364237B (zh) | 2016-08-24 |
| US9155739B2 (en) | 2015-10-13 |
| RU2629947C2 (ru) | 2017-09-05 |
| TWI481597B (zh) | 2015-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02104A (enrdf_load_stackoverflow) | ||
| WO2012173682A3 (en) | Compounds and methods for the treatment of isocitrate dehydrognase related diseases | |
| MX2021005561A (es) | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco. | |
| MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
| PH12015502658A1 (en) | 3,4-dihydroisoquinolin-2 (1h)-yl compounds | |
| DOP2016000124A (es) | Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo | |
| CR20140413A (es) | Inhibidores de serina/treonina cinasa | |
| MD20160017A2 (ro) | Polimorf al inhibitorilor SYK | |
| MX2018001990A (es) | Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac. | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
| MD4684B1 (ro) | Formulări pe bază de imidazopirazine în calitate de inhibitori SYK | |
| MX2015003728A (es) | Combinacion de regorafenib y acido acetilsalicilico para el tratamiento del cancer. | |
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| PH12015501586A1 (en) | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors | |
| IN2015DN01119A (enrdf_load_stackoverflow) | ||
| PH12013501800A1 (en) | Tricyclic gyrase inhibitors | |
| IN2012DN02556A (enrdf_load_stackoverflow) | ||
| BR112012031340A2 (pt) | derivados de cianoquinolina | |
| WO2014163622A8 (en) | Multifunctional quinoline derivatives as anti-neurodegenerative agents | |
| WO2014160177A3 (en) | Quinazoline inhibitors of pi3k | |
| IN2014DN08443A (enrdf_load_stackoverflow) | ||
| PH12014502747A1 (en) | Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide |